Text Size

Impact of Follicular and Blood G-CSF on Pregnancy and Implantation Rate During Modified Natural in Vitro Fertility Cycle (G-CSF FIVnat)

This study is currently recruiting participants.
Verified August 2012 by OVO R & D
Sponsor:
Information provided by (Responsible Party):
OVO R & D
ClinicalTrials.gov Identifier:
NCT01668225
First received: June 19, 2012
Last updated: August 14, 2012
Last verified: August 2012
History of Changes
  Purpose

Recently, scientists look into G-CSF (Granulocyte - Colony Stimulatin Factor). The use of this molecule is increasing in reproduction pathology. High level of follicular and blood G-CSF on the day of oocyte retrieval could correlate with higher pregnancy and implantation rates.


Condition Intervention
Fertility Diseases
 Procedure: Blood sample

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Impact of Follicular and Blood G-CSF on Pregnangcy and Implantation Rate During Modified Natural in Vitro Fertility Cycle

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by OVO R & D:

Primary Outcome Measures:
  • Serum and / or follicular minimum level of G-CSF predictive of pregnancy [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples Without DNA

Serum sample Follicular fluid


Estimated Enrollment: 224
Study Start Date: March 2012
Groups/Cohorts Assigned Interventions
G-CSF FIV nat
Patient following a natural In Vitro Fecondation cycle
 Procedure: Blood sample

Taking blood sample of the patient during the day 3, triggering day, oocyte collection day and pregnancy test day.

Taking the follicular fluid during the oocyte collection day

  Eligibility

Ages Eligible for Study:   18 Years to 43 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Women with a natural cycle of an In Vitro Fecondation

Criteria

Inclusion Criteria:

  • Women between 18 and 43 years old
  • Women natural In Vitro Fecondation

Exclusion Criteria:

  • No exclusion criteria
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01668225

Contacts
Contact: Cynthia Levesque (514) 798-2000 ext 755 c.levesque@cliniqueovo.com
Contact: Michael Harnois (514) 798-2000 ext 755 m.harnois@cliniqueovo.com

Locations
Canada, Quebec
Ovo Fertilité Recruiting
Montréal, Quebec, Canada, J4P 2S4
Contact: Shirley Brugerie     (514) 798-2000 ext 753     s.brugerie@cliniqueovo.com    
Sponsors and Collaborators
OVO R & D
Investigators
Principal Investigator: Pierre Lehmann, MD Clinique ovo
  More Information

No publications provided

Responsible Party: OVO R & D
ClinicalTrials.gov Identifier: NCT01668225     History of Changes
Other Study ID Numbers: OVO-11-02
Study First Received: June 19, 2012
Last Updated: August 14, 2012
Health Authority: Canada: Ethics Committee

ClinicalTrials.gov processed this record on June 18, 2013